论文部分内容阅读
目的对比观察术后辅助化疗对非小细胞肺癌患者生存期的作用。方法选取2007年1月~2008年8月在本院接受ⅠB~ⅢA期行完全性切除的60例非小细胞肺癌患者,将60例患者术后接受长春瑞滨+顺铂(NP)方案或紫杉醇+卡铂(TP)方案化疗的32例患者设为治疗组,将27例仅接受术后观察的患者设为对照组,采用Kaplan-Meier法分析两组患者第1、第2、第3、第4年生存率,同时对患者中位生存时间进行分析。结果观察组接受辅助化疗患者第1年的生存率为90.6%,第2年生存率为81.3%,第3年生存率62.5%,第四年生存率37.5%,对照组患者第1年生存率为78.6%,第2年生存率为64.3%,第3年生存率为50.0%,第四年生存率为32.1%,观察组患者第1、第2、第3、第4年生存率均高于对照组患者生存率,差异有统计学意义(P<0.05)。结论完全切除病灶的ⅠB~ⅢA期非小细胞肺癌患者的术后生存期能够通过术后含铂辅助化疗得到有效延长。
Objective To compare the effect of postoperative adjuvant chemotherapy on the survival of non-small cell lung cancer patients. Methods Sixty patients with non-small cell lung cancer (NSCLC) who undergone complete resection of stage ⅠB-ⅢA in our hospital from January 2007 to August 2008 were enrolled. Sixty patients were treated with vinorelbine + cisplatin (NP) Thirty-two patients receiving paclitaxel + carboplatin (TP) regimen as the treatment group, 27 patients receiving only postoperative observation as the control group, Kaplan-Meier analysis of two groups of patients 1, 2, 3 , 4th year survival rate, while the median survival time of patients were analyzed. Results The survival rate of the patients in the observation group was 90.6% in the first year, 81.3% in the second year, 62.5% in the third year and 37.5% in the fourth year. The 1 year survival rate of the control group Was 78.6%, the second year survival rate was 64.3%, the third year survival rate was 50.0% and the fourth year survival rate was 32.1%. The observation group patients had the highest survival rate at the first, the second, the third and the fourth years The survival rate of patients in the control group, the difference was statistically significant (P <0.05). Conclusions The postoperative survival of patients with stage IB-IIIA non-small cell lung cancer with complete resection of the lesion can be effectively prolonged by postoperative platinum-containing adjuvant chemotherapy.